DE19802139C1 - Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung - Google Patents

Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Info

Publication number
DE19802139C1
DE19802139C1 DE19802139A DE19802139A DE19802139C1 DE 19802139 C1 DE19802139 C1 DE 19802139C1 DE 19802139 A DE19802139 A DE 19802139A DE 19802139 A DE19802139 A DE 19802139A DE 19802139 C1 DE19802139 C1 DE 19802139C1
Authority
DE
Germany
Prior art keywords
factor vii
monoclonal antibody
activated factor
activated
fviia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE19802139A
Other languages
German (de)
English (en)
Inventor
Juergen Roemisch
Wiegand Lang
Annette Feusner
Joachim Roeder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
Centeon Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centeon Pharma GmbH filed Critical Centeon Pharma GmbH
Priority to DE19802139A priority Critical patent/DE19802139C1/de
Priority to EP98124672A priority patent/EP0931793B1/de
Priority to AT98124672T priority patent/ATE261991T1/de
Priority to DE59810998T priority patent/DE59810998D1/de
Priority to ES98124672T priority patent/ES2217492T3/es
Priority to CA2259724A priority patent/CA2259724C/en
Priority to KR1019990001775A priority patent/KR100583537B1/ko
Priority to JP01261099A priority patent/JP4422228B2/ja
Priority to US09/234,504 priority patent/US6479245B1/en
Priority to AU13185/99A priority patent/AU742631B2/en
Application granted granted Critical
Publication of DE19802139C1 publication Critical patent/DE19802139C1/de
Priority to US10/226,118 priority patent/US6835817B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE19802139A 1998-01-22 1998-01-22 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung Expired - Fee Related DE19802139C1 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE19802139A DE19802139C1 (de) 1998-01-22 1998-01-22 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
EP98124672A EP0931793B1 (de) 1998-01-22 1998-12-24 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
AT98124672T ATE261991T1 (de) 1998-01-22 1998-12-24 Monoklonaler antikörper spezifisch für aktivierten gerinnungsfaktor vii und seine verwendung
DE59810998T DE59810998D1 (de) 1998-01-22 1998-12-24 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
ES98124672T ES2217492T3 (es) 1998-01-22 1998-12-24 Anticuerpo monoclonal, especifico para el factor de coagulacion vii activado y su utilizacion.
CA2259724A CA2259724C (en) 1998-01-22 1999-01-20 Monoclonal antibody which is specific for activated coagulation factor vii, and its use
KR1019990001775A KR100583537B1 (ko) 1998-01-22 1999-01-21 활성화된 응고 인자 ｖｉｉ에 특이적인 모노클로날 항체 및 이의 용도
JP01261099A JP4422228B2 (ja) 1998-01-22 1999-01-21 活性化血液凝固第ｖｉｉ因子に特異的なモノクローナル抗体およびその使用
US09/234,504 US6479245B1 (en) 1998-01-22 1999-01-21 Monoclonal antibody which is specific for activated coagulation factor VII, and its use
AU13185/99A AU742631B2 (en) 1998-01-22 1999-01-21 Monoclonal antibody which is specific for activated coagulation factor VII, and its use
US10/226,118 US6835817B2 (en) 1998-01-22 2002-08-23 Monoclonal antibody which is specific for activated coagulation factor VII, and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19802139A DE19802139C1 (de) 1998-01-22 1998-01-22 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Publications (1)

Publication Number Publication Date
DE19802139C1 true DE19802139C1 (de) 1999-09-23

Family

ID=7855234

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19802139A Expired - Fee Related DE19802139C1 (de) 1998-01-22 1998-01-22 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
DE59810998T Expired - Lifetime DE59810998D1 (de) 1998-01-22 1998-12-24 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59810998T Expired - Lifetime DE59810998D1 (de) 1998-01-22 1998-12-24 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Country Status (9)

Country Link
US (2) US6479245B1 (enExample)
EP (1) EP0931793B1 (enExample)
JP (1) JP4422228B2 (enExample)
KR (1) KR100583537B1 (enExample)
AT (1) ATE261991T1 (enExample)
AU (1) AU742631B2 (enExample)
CA (1) CA2259724C (enExample)
DE (2) DE19802139C1 (enExample)
ES (1) ES2217492T3 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
MXPA03005273A (es) * 2000-12-14 2003-09-25 Genentech Inc Anticuerpos producidos procarioticamente y sus usos.
US7494782B2 (en) * 2001-07-03 2009-02-24 Morrissey James H Assay for measuring factor viia-antithrombin complexes
EP3956359A1 (en) 2019-04-17 2022-02-23 Novo Nordisk A/S Bispecific antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Thromb. Res. 1992, 68 (3), S.269-81 *

Also Published As

Publication number Publication date
AU742631B2 (en) 2002-01-10
KR100583537B1 (ko) 2006-05-26
CA2259724A1 (en) 1999-07-22
JP4422228B2 (ja) 2010-02-24
JPH11279199A (ja) 1999-10-12
US6479245B1 (en) 2002-11-12
CA2259724C (en) 2010-07-13
ES2217492T3 (es) 2004-11-01
DE59810998D1 (de) 2004-04-22
US6835817B2 (en) 2004-12-28
US20030003096A1 (en) 2003-01-02
EP0931793A1 (de) 1999-07-28
EP0931793B1 (de) 2004-03-17
AU1318599A (en) 1999-08-12
KR19990068047A (ko) 1999-08-25
ATE261991T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
DE3486262T2 (de) Verfahren zur Herstellung eines monoklonalen Antikörpers mit Spezifizität für vernetzte Fibrinderivate und ein Testverfahren mittels dieses Antikörpers.
DE3486030T2 (de) Monoklonale antikoerper, spezifisch von in vivo von fibrinogen abgeleiteten derivatstuecken.
EP0038935B1 (de) Verfahren zur immunologischen Bestimmung von Enzymen, Mittel zur Durchführung des Verfahrens und seine Verwendung
EP2168985B1 (de) Antikörper zur Bestimmung des Prothrombin-Fragments F2/F1+2 in einem homogenen Immunoassay
DE19538715A1 (de) Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
EP1074616A1 (de) Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
EP1650305B1 (de) Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern
DE19802139C1 (de) Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
DE3876124T2 (de) Immunoassay fuer thrombomodulin.
EP1334983B1 (de) Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII akitivierende Protease
DE69129582T2 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE3875826T2 (de) Methode, vorrichtung und testsatz zur messung der aktivitaet eines gewebeplasminogenaktivators.
DE68911574T2 (de) Reagenzsystem zur Bestimmung des Komplexes des menschlichen Plasminogenaktivator-Inhibitors und des menschlichen Gewebeplasminogenaktivators und Testsatz dafür.
DE3789284T2 (de) Immunologische Bestimmung von freiem menschlichem Protein-S und c4bp-Protein-S-Komplex.
DE3882411T2 (de) Verfahren zur Trennung von aktiviertem menschlichem Protein C.
DE69529106T2 (de) Monoklonaler Antikörper gegen denThrombin-Antithrombin III-Komplex und dessen Verwendung in Immunoassays
DE19820328A1 (de) Verfahren und Reagenz zum Nachweis apoptotischer Zellen bzw. einer bei Apoptose aktivierten Protease
DE3855007T2 (de) METHODE ZUR REINIGUNG REKOMBINANTER t-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN
DE3687542T2 (de) Monoklonaler antikoerper gegen humanes protein c.
EP0513565B1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DE60034660T2 (de) Monoklonaler antikörper gegen protein c inhibitor
WO1993021532A1 (de) METHODE ZUR BESTIMMUNG VON PLASMIN-α2-ANTIPLASMIN KOMPLEXEN SOWIE VERWENDUNG DER BESTIMMUNGSMETHODE ALS MASS FÜR VERÄNDERUNGEN IM FIBRINOLYTISCHEN SYSTEM
DE19634312A1 (de) Verfahren zur Herstellung von Faktor V-Mangelplasma und ein so erhaltenes Mangelplasma
DE10036641A1 (de) Monoklonale Antikörper für die den Blutgerinnungsfaktor VII aktivierende Protease (FSAP)und ihre Verwendung
DE19538716A1 (de) Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)

Legal Events

Date Code Title Description
8100 Publication of patent without earlier publication of application
D1 Grant (no unexamined application published) patent law 81
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS BEHRING GMBH, 35041 MARBURG, DE

8339 Ceased/non-payment of the annual fee